Business Wire

Morinaga Milk’s Probiotic Bifidobacterium longum BB536 Achieves Self-Affirmed GRAS for Infants in Celebration of Its 50th Anniversary

Share

Morinaga Milk Industry Co., Ltd. (TOKYO:2264), a leading Japanese dairy product company, today announced its proprietary probiotic Morinaga Bifidobacterium longum BB536 has received self-affirmed GRAS (Generally Recognized as Safe) for infant formulas, in honor of its 50th anniversary.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190709005021/en/

Figure 1. Beneficial effects of Bifidobacterium longum BB536 on human health. (Graphic: Business Wire)

Figure 1. Beneficial effects of Bifidobacterium longum BB536 on human health. (Graphic: Business Wire)

Bifidobacterium longum BB536, a clinically proven multifunctional probiotic strain that was originated from the gut of a healthy breast-fed infant in 1969, is celebrating its 50th anniversary of its discovery in 2019.

The probiotic strain Bifidobacterium longum BB536 had previously attained official confirmation from the U.S. Food and Drug Administration (FDA) and was recognized as safe and suitable for use in a variety of food products and dietary supplements (GRAS Notice No. GRN 000268). With this newest self-affirmed GRAS status, Morinaga Milk is now expanding the opportunities of its flagship probiotic strain BB536 into the new space – to be specifically used in infant formulas.

Following a comprehensive and critical evaluation of the safety of B. longum BB536, the strain was deemed Generally Recognized As Safe (GRAS) for use as a probiotic ingredient in infant formula. The evaluation was conducted by an independent panel of qualified scientific experts, advised by Claire Kruger, Ph.D., D.A.B.T., president of Rockville, MD-based Spherix Consulting, to ensure that BB536 meets the highest standards of safety and regulatory compliance. The company said it will submit a GRAS Notification for BB536 to the FDA.

“This incredible achievement is yet another indication of our commitment to continuously strive to add value to our flagship probiotic strain, the foundation of which lies in safety and efficacy,” said Ko Shiino, General Manager of Sales and Marketing Department, International Division of Morinaga Milk. “The new GRAS status is also a stepping stone in our efforts to further backing the scientific rigor of our proprietary probiotic strain. We are extremely delighted that BB536 has passed the stringent process to obtain the new GRAS status pertaining to infants,” he added. Further, the potential implications of this new status are very exciting to be a part of.

First Among Many: Publication of A Strain-Specific Scientific Review

Embracing a major milestone, Morinaga Milk is also proud to announce the publication of a scientific review on the clinical efficacy and safety of its flagship probiotic strain BB536. In tandem with the 50th anniversary of the discovery of BB536, the publication of the review (Wong et al., 2019) in Journal of Functional Foods provides a comprehensive overview on the huge amount of scientific information available regarding health benefits, safety, and mechanism of actions of BB536 as a multifunctional human probiotic.

“We are extremely honored to have BB536 to stand out from the many undocumented strains being marketed speciously as probiotics. This scientific review would serve as a fundamental framework to better understand the clinical effectiveness of BB536 and how such beneficial effects take place,” said Dr. Xiao, General Manager of Next Generation Science Institute of Morinaga Milk. “We strongly believe that the publication of this scientific review can provide both medical care professionals and the public more reliable health claims in helping them to make better-informed probiotics selection,” he noted.

BB536 Celebrates 50 Years of Empowering Better Health

BB536 is a clinically effective, well-established, multifunctional probiotic strain that has a long history of human use in alleviating gastrointestinal, immunological and infectious diseases. For half a century, BB536 has been the superior Human-Residential Bifidobacteria (HRB) probiotic strain that helps people achieve optimal health from the inside out. Ingestion of BB536 can provide a consistent beneficial effect in improvement of gastrointestinal conditions, maintenance of intestinal microflora balance, regulation of immune response, anti-allergy, and protection against microbial infections. It is evidenced that BB536 acts in concert with the gut microbiota to drive a fine-tuned intestinal and immune balance.

BB536 has been used as a functional food ingredient in various products such as milk-based drink, yogurt, infant formula, and nutritional supplements and has been marketed in over 30 countries for more than 40 years. “In fact, BB536 is considered as one of the best characterized probiotic and has gained importance thanks to its substantial beneficial effects in the treatment and management of human health without any adverse effects,” the company adds.

Backed by Human Substantiation, Safety and Efficacy

“Along with an exceptionally long history of safe use in humans, as published in the review, the safety and efficacy of BB536 continues to be undoubtedly proven through solid science, leading to the receipt of self-affirmed GRAS approval,” said Dr. Abe, Corporate Officer and General Manager of Food Ingredients & Technology Institute of Morinaga Milk.

In recent years, probiotics have become increasingly popular in infant products as awareness continue to rise around the importance of stimulating beneficial bacteria from the beginning of life for prevention against various health-related complications. However, as the use and diversity of probiotic products expand, choosing an appropriate type of probiotic has been challenging due to differences in the mechanisms of action, safety profile, origin, and efficacy of different strains. Questions and concerns have been raised about the safety and clinical efficacy of probiotic administration, especially if the product is destined for use in infants.

“Affirmation of this important self-affirmed GRAS status confirms that the science behind the probiotic strain BB536 is sufficient to guarantee its safety in infant formula. This greatly allows us to diversify the application options available to our customers,” he added.

About Morinaga

Morinaga Milk Industry Co., Ltd. is one of the leading dairy product companies in Japan with a century of history harnessing the nutritional properties of dairy products and its functional ingredients. Morinaga Milk excels in innovative technology and offers various dairy products and other beneficial functional ingredients to customers throughout the world. Since 1960s, Morinaga Milk has been engaged in research on the safety, functional health benefits, and mechanisms of action of probiotic bifidobacteria to better understand their role in maintaining human health. For more information about Morinaga Bifidobacteria, please visit us at http://bb536.jp/english/index.html.

Contact information

Chyn Boon Wong
Morinaga Milk Industry Co., Ltd.
+81-3-3798-0152
chynboon020@morinagamilk.co.jp
http://www.morinagamilk.co.jp/english/

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

EURid Launches New Eligibility Criteria19.10.2019 04:30:00 CESTPress release

The top-level internet domain .eu is the eighth largest country code extension on the internet and, as of October 2019, we have more than 3.6 million registrations spread out across Europe. Since its launch in 2006, only companies and individuals residing within the EU and EEA member states have been eligible to register the .eu domain name. However, striving to meet the needs of an ever-changing digital environment, the eligibility criteria for the registration of .eu domain name has now been extended to all EU citizens living around the world. With millions of Europeans living around the world – our hope is to provide these individuals, living far from their native lands, with a personal online platform through which they can share their stories with families and friends back home. “We are excited to be able to extend the registration criteria to EU citizens around the world. The .eu domain is now closer to your ambitions, achievements and dreams. It is the bridge connecting you to y

ams to Launch New Takeover Offer for OSRAM at EUR 41.00 Per Share With Minimum Acceptance Threshold of 55%18.10.2019 17:16:00 CESTPress release

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION (IN WHOLE OR IN PART) IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION ams (SIX: AMS), a leading worldwide supplier of high performance sensor solutions, announces that it intends to launch a new all-cash takeover offer for OSRAM Licht AG ("OSRAM") for 100% of the share capital of OSRAM at a price of EUR 41.00 per share ("Offer"). The Offer which represents a premium of 42% to the undisturbed OSRAM share price of EUR 28.92 as of 2 July 2019 will be launched by ams Offer GmbH, a newly incorporated, wholly owned subsidiary of ams. ams is the largest shareholder in OSRAM with a direct shareholding of 19.99% which ams will not exceed outside of the Offer. As a result of ams' shareholder position, ams has lowered the minimum acceptance threshold to 55%. Winning way forward for ams and OSRAM The combination of ams and OSRAM allows ams to create a global leader in sensor solutio

Resecurity Appoints Selene Giupponi Managing Director of Resecurity Europe18.10.2019 15:38:00 CESTPress release

Resecurity, a cybersecurity company that delivers in-depth analysis layered on top of the most comprehensive, exclusive sets of data from the Deep and Dark Web, announces that Selene Giupponi has joined as Managing Director and will be based in Italy. A digital forensics expert, Selene adds significant value to Resecurity’s operations in Europe. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191018005415/en/ Resecurity Appoints Selene Giupponi Managing Director of Resecurity Europe (Photo: Business Wire) Selene has extensive expertise in digital forensics and is often called as an expert witness regarding digital and mobile forensics on domestic and international cases, investigations and court trials. She is a specialized IT trainer in Italy and teaches digital, mobile, cloud and mainframe forensics, cybercrime and information security at various Italian universities. “Selene brings a depth of experience to our team and we

Secure-24 Completes Acquisition of Symmetry Corporation18.10.2019 14:20:00 CESTPress release

NTT Ltd., the newly formed, world-leading global technology services provider, and Symmetry Holding Inc. (Symmetry), a U.S.-based leading provider of SAP managed services, today announced that Secure-24 Intermediate Holdings, Inc. (Secure-24), part of the Managed Services division of NTT Ltd., has completed the acquisition of Symmetry Corporation effective October 17, 2019. “The powerful business combination of Secure-24 and Symmetry leverages the strengths of both companies around Secure-24’s foundation of delivering managed IT operations, application hosting and cloud services to enterprises worldwide,” said Mike BeDell, Chief Executive Officer, Secure-24. “As we begin to integrate Symmetry’s portfolio into Secure-24’s portfolio, through a shared vision, we look forward to providing even greater value that accelerates our clients’ business success.” Symmetry, headquartered in Brookfield, Wisconsin, will expand the scale of SAP managed services capabilities of Secure-24 and bring new

New Research Reveals Updated Patient Preferences on Digital Health Technology18.10.2019 13:00:00 CESTPress release

ResMed (NYSE: RMD, ASX: RMD) today announced results from a company-led survey, revealing new patient preferences on digital health technology. The survey highlights a reason for optimism that the markets for digital health technology will only continue to grow. The survey of a nationally representative sample of 3,000 Americans, conducted in partnership with Edelman Intelligence, revealed that the use of – and confidence in – remote digital health technology is widespread: 56% of those surveyed currently monitor their health with at least one digital data collection tool. Also, 60% of people attempt to diagnose themselves after browsing symptoms on the Internet – including 76% of Millennials. Perhaps more surprising, remote digital health technology seems to have deepened people’s connection with their physicians rather than distanced them from one another. Over half of those surveyed agree that technology has improved their relationship with their primary care provider, and many woul

CHMP Grants Positive Opinion for Expanded Use of Janssen’s Darzalex®▼(daratumumab) for Patients with Newly Diagnosed Multiple Myeloma Who Are Transplant Ineligible18.10.2019 12:43:00 CESTPress release

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended broadening the existing marketing authorisation for Darzalex® (daratumumab) to include the use of daratumumab in combination with lenalidomide and dexamethasone (DRd) for patients with newly diagnosed multiple myeloma (NDMM) who are ineligible for autologous stem cell transplant (ASCT). “As multiple myeloma can become more complex with each relapse, it is important that patients receive the latest treatment options with the goal of extending their first remission period,” said Professor Thierry Facon, M.D., Service des Maladies du Sang, Hôpital Claude Huriez, Lille, France, and principal investigator of the MAIA study. “For newly diagnosed patients who are transplant ineligible, this regimen could be an important frontline therapy option and reinforces the consistent clinical profile of daratumuma